The Indiana University Melvin and Bren Simon Cancer Center is a matrix Cancer Center that organizes and facilitates cancer research, education, patient care, and cancer control and prevention. Our mission is to advance the understanding, prevention and treatment of cancer throughout Indiana and the world with patient centered care, acceleration of promising science and collaborative educational programs. This application seeks funds for the Center's four research programs, six shared facilities, Protocol-Specific Research, Protocol Review and Monitoring System, and Data and Safety Monitoring. In addition, funds are requested for Administration, Program Planning and Evaluation, Developmental Funds, and Senior Leaders. The research programs have been organized and developed to be highly interactive, allowing for successful collaboration among basic, clinical, and population science researchers. The research programs are: 1) Cancer Control, 2) Breast Cancer, 3) Experimental and Developmental Therapeutics, 4) Hematopoiesis, Microenvironment and Immunology. Supporting the members of these programs are six shared resources: Biological Microscopy, Biostatistics and Data Management, Clinical Research Office, Flow Cytometry, Chemical Genomics and Clinical Pharmacology Analytical Analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA082709-14S5
Application #
8727147
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1999-09-22
Project End
2014-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
14
Fiscal Year
2013
Total Cost
$99,923
Indirect Cost
$35,870
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Kedage, Vivekananda; Selvaraj, Nagarathinam; Nicholas, Taylor R et al. (2016) An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer. Cell Rep 17:1289-1301
Nudelman, Kelly N H; McDonald, Brenna C; Wang, Yang et al. (2016) Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy. J Clin Oncol 34:677-83
Hoggatt, Jonathan; Hoggatt, Amber F; Tate, Tiffany A et al. (2016) Bleeding the laboratory mouse: Not all methods are equal. Exp Hematol 44:132-137.e1
Haley, James; Tomar, Sunil; Pulliam, Nicholas et al. (2016) Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease. Oncotarget 7:32810-20
Radovich, Milan; Solzak, Jeffrey P; Hancock, Bradley A et al. (2016) A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas. Br J Cancer 114:477-84
Li, Wei; Liu, Liangyi; Gomez, Aurelie et al. (2016) Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease. JCI Insight 1:
Champion, Victoria L; Rawl, Susan M; Bourff, Sara A et al. (2016) Randomized trial of DVD, telephone, and usual care for increasing mammography adherence. J Health Psychol 21:916-26
Meijome, Tomas E; Baughman, Jenna T; Hooker, R Adam et al. (2016) C-Mpl Is Expressed on Osteoblasts and Osteoclasts and Is Important in Regulating Skeletal Homeostasis. J Cell Biochem 117:959-69
Richine, B M; Virts, E L; Bowling, J D et al. (2016) Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia. Leukemia 30:2094-2097
Masters, Andrea R; Gufford, Brandon T; Lu, Jessica Bo Li et al. (2016) Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers. J Pharmacol Exp Ther 358:230-8

Showing the most recent 10 out of 220 publications